P50: A candidate ERP biomarker of prodromal Alzheimer壮s disease
详细信息 查看全文
- 作者：Deborah L. Greena ; 1 ; Deborah.Green4@va.gov" class="auth_mail" title="E-mail the corresponding author ; Lisa Payneb ; 2 ; Robi Polikarc ; Paul J. Mobergd ; David A. Wolke ; John Kouniosa
- 关键词：P50 ; Alzheimer壮s disease (AD) ; Event-related potential (ERP) ; Auditory oddball paradigm ; Cerebrospinal fluid biomarkers ; Amyloid-beta
- 刊名：Brain Research
- 出版年：2015
- 出版时间：22 October 2015
- 年：2015
- 卷：1624
- 期：Complete
- 页码：390-397
- 全文大小：688 K
文摘
- •
We investigated the P50 component as a biomarker of Alzheimer壮s disease (AD).
- •
Participants included non-demented patients with mild cognitive impairment (MCI).
- •
P50 amplitude was larger in amyloid-positiverelative to amyloid–negative patients.
- •
P50 amplitude predicted cerebrospinal fluid amyloid status in the MCI patients.
- •
This is consistent with MCI to AD converters having shown larger P50 at baseline.
- •
P50 may prove to be a useful biomarker for early, even pre-symptomatic, AD.